Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics.
Identifieur interne : 000656 ( Main/Exploration ); précédent : 000655; suivant : 000657Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics.
Auteurs : Peng H. Tan [Royaume-Uni] ; Amrit S. LotaSource :
- Expert opinion on pharmacotherapy [ 1744-7666 ] ; 2008.
Descripteurs français
- KwdFr :
- Aisselle (chirurgie), Anticorps monoclonaux (usage thérapeutique), Association thérapeutique (MeSH), Femelle (MeSH), Humains (MeSH), Lymphadénectomie (MeSH), Tamoxifène (usage thérapeutique), Tumeurs du sein (chirurgie), Tumeurs du sein (immunologie), Tumeurs du sein (radiothérapie), Tumeurs du sein (thérapie), Tumeurs du sein (traitement médicamenteux), Vaccins anticancéreux (usage thérapeutique).
- MESH :
- chirurgie : Aisselle, Tumeurs du sein.
- immunologie : Tumeurs du sein.
- radiothérapie : Tumeurs du sein.
- thérapie : Tumeurs du sein.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Anticorps monoclonaux, Tamoxifène, Vaccins anticancéreux.
- Association thérapeutique, Femelle, Humains, Lymphadénectomie.
English descriptors
- KwdEn :
- Antibodies, Monoclonal (therapeutic use), Axilla (surgery), Breast Neoplasms (drug therapy), Breast Neoplasms (immunology), Breast Neoplasms (radiotherapy), Breast Neoplasms (surgery), Breast Neoplasms (therapy), Cancer Vaccines (therapeutic use), Combined Modality Therapy (MeSH), Female (MeSH), Humans (MeSH), Lymph Node Excision (MeSH), Tamoxifen (therapeutic use).
- MESH :
- chemical , therapeutic use : Antibodies, Monoclonal, Cancer Vaccines, Tamoxifen.
- drug therapy : Breast Neoplasms.
- immunology : Breast Neoplasms.
- radiotherapy : Breast Neoplasms.
- surgery : Axilla, Breast Neoplasms.
- therapy : Breast Neoplasms.
- Combined Modality Therapy, Female, Humans, Lymph Node Excision.
Abstract
Early diagnosis and treatment of breast cancer may account for the current improvement in the mortality of breast cancer. However, achieving a complete 'cure' is the holy grail of cancer medicine and, in many cases, cancer patients still succumb to their ultimate fate. There is therefore a need to devise innovative therapies to overcome this problem. To this end, many emerging therapies utilizing the immune system to eradicate the residues of disease have been described in the preclinical and clinical arenas. However, there is very little work examining the impact of immunotherapy on the existing natural immunity. The relationship between antitumor immunity, in the form of immunotherapy (either passive or active), and current strategies of treatment also needs to be explored. If we are to improve the success of cancer treatment, we must understand how current therapies interact with the immune system and with the emerging immunotherapies. For breast-cancer treatment to be successful, therapeutics should be tailored towards antitumor immunity; they should also avoid tumor-specific tolerance. The sources of information used to prepare this paper were obtained through published work on Pubmed/Medline and materials published on the US/UK governmental agencies' websites.
DOI: 10.1517/14656566.9.15.2639
PubMed: 18803451
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000088
- to stream PubMed, to step Curation: 000088
- to stream PubMed, to step Checkpoint: 000090
- to stream Ncbi, to step Merge: 000129
- to stream Ncbi, to step Curation: 000129
- to stream Ncbi, to step Checkpoint: 000129
- to stream Main, to step Merge: 000665
- to stream Main, to step Curation: 000656
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics.</title><author><name sortKey="Tan, Peng H" sort="Tan, Peng H" uniqKey="Tan P" first="Peng H" last="Tan">Peng H. Tan</name><affiliation wicri:level="4"><nlm:affiliation>University of Oxford, The John Radcliffe Hospital, Nuffield Department of Surgery, Headley Way, Oxford, OX3 9DU, UK. peng.tan@nds.ox.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Oxford, The John Radcliffe Hospital, Nuffield Department of Surgery, Headley Way, Oxford, OX3 9DU</wicri:regionArea><orgName type="university">Université d'Oxford</orgName><placeName><settlement type="city">Oxford</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Oxfordshire</region></placeName></affiliation></author><author><name sortKey="Lota, Amrit S" sort="Lota, Amrit S" uniqKey="Lota A" first="Amrit S" last="Lota">Amrit S. Lota</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="doi">10.1517/14656566.9.15.2639</idno><idno type="RBID">pubmed:18803451</idno><idno type="pmid">18803451</idno><idno type="wicri:Area/PubMed/Corpus">000088</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000088</idno><idno type="wicri:Area/PubMed/Curation">000088</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000088</idno><idno type="wicri:Area/PubMed/Checkpoint">000090</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000090</idno><idno type="wicri:Area/Ncbi/Merge">000129</idno><idno type="wicri:Area/Ncbi/Curation">000129</idno><idno type="wicri:Area/Ncbi/Checkpoint">000129</idno><idno type="wicri:Area/Main/Merge">000665</idno><idno type="wicri:Area/Main/Curation">000656</idno><idno type="wicri:Area/Main/Exploration">000656</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics.</title><author><name sortKey="Tan, Peng H" sort="Tan, Peng H" uniqKey="Tan P" first="Peng H" last="Tan">Peng H. Tan</name><affiliation wicri:level="4"><nlm:affiliation>University of Oxford, The John Radcliffe Hospital, Nuffield Department of Surgery, Headley Way, Oxford, OX3 9DU, UK. peng.tan@nds.ox.ac.uk</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>University of Oxford, The John Radcliffe Hospital, Nuffield Department of Surgery, Headley Way, Oxford, OX3 9DU</wicri:regionArea><orgName type="university">Université d'Oxford</orgName><placeName><settlement type="city">Oxford</settlement><region type="nation">Angleterre</region><region type="région" nuts="1">Oxfordshire</region></placeName></affiliation></author><author><name sortKey="Lota, Amrit S" sort="Lota, Amrit S" uniqKey="Lota A" first="Amrit S" last="Lota">Amrit S. Lota</name></author></analytic><series><title level="j">Expert opinion on pharmacotherapy</title><idno type="eISSN">1744-7666</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Monoclonal (therapeutic use)</term><term>Axilla (surgery)</term><term>Breast Neoplasms (drug therapy)</term><term>Breast Neoplasms (immunology)</term><term>Breast Neoplasms (radiotherapy)</term><term>Breast Neoplasms (surgery)</term><term>Breast Neoplasms (therapy)</term><term>Cancer Vaccines (therapeutic use)</term><term>Combined Modality Therapy (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Lymph Node Excision (MeSH)</term><term>Tamoxifen (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Aisselle (chirurgie)</term><term>Anticorps monoclonaux (usage thérapeutique)</term><term>Association thérapeutique (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Lymphadénectomie (MeSH)</term><term>Tamoxifène (usage thérapeutique)</term><term>Tumeurs du sein (chirurgie)</term><term>Tumeurs du sein (immunologie)</term><term>Tumeurs du sein (radiothérapie)</term><term>Tumeurs du sein (thérapie)</term><term>Tumeurs du sein (traitement médicamenteux)</term><term>Vaccins anticancéreux (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Cancer Vaccines</term><term>Tamoxifen</term></keywords><keywords scheme="MESH" qualifier="chirurgie" xml:lang="fr"><term>Aisselle</term><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Axilla</term><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux</term><term>Tamoxifène</term><term>Vaccins anticancéreux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Combined Modality Therapy</term><term>Female</term><term>Humans</term><term>Lymph Node Excision</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Association thérapeutique</term><term>Femelle</term><term>Humains</term><term>Lymphadénectomie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Early diagnosis and treatment of breast cancer may account for the current improvement in the mortality of breast cancer. However, achieving a complete 'cure' is the holy grail of cancer medicine and, in many cases, cancer patients still succumb to their ultimate fate. There is therefore a need to devise innovative therapies to overcome this problem. To this end, many emerging therapies utilizing the immune system to eradicate the residues of disease have been described in the preclinical and clinical arenas. However, there is very little work examining the impact of immunotherapy on the existing natural immunity. The relationship between antitumor immunity, in the form of immunotherapy (either passive or active), and current strategies of treatment also needs to be explored. If we are to improve the success of cancer treatment, we must understand how current therapies interact with the immune system and with the emerging immunotherapies. For breast-cancer treatment to be successful, therapeutics should be tailored towards antitumor immunity; they should also avoid tumor-specific tolerance. The sources of information used to prepare this paper were obtained through published work on Pubmed/Medline and materials published on the US/UK governmental agencies' websites.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Oxfordshire</li></region><settlement><li>Oxford</li></settlement><orgName><li>Université d'Oxford</li></orgName></list><tree><noCountry><name sortKey="Lota, Amrit S" sort="Lota, Amrit S" uniqKey="Lota A" first="Amrit S" last="Lota">Amrit S. Lota</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Tan, Peng H" sort="Tan, Peng H" uniqKey="Tan P" first="Peng H" last="Tan">Peng H. Tan</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Eau/explor/LotaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000656 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000656 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Eau
|area= LotaV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:18803451
|texte= Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:18803451" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LotaV3
| This area was generated with Dilib version V0.6.39. |  |